English
|
中文
HOME
NEWS
EVENTS
Conference
Exhibition
Laws & Regulations
About Us
CAIVD & PCEM
CAIVD
PCEM
VIEW
About VIEW
Editorial Board
Contact
Search
News
Home
>
News
Siemens Healthineers enters new fiscal year with sustained strength in orders and confirms outlook
2023-02-06
Siemens Healthineers AG today announces its results for the first quarter of fiscal year 2023, ending December 31, 2022.
BD Reports First Quarter Fiscal 2023 Financial Results
2023-02-06
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced results for its first quarter of fiscal 2023, which ended December 31, 2022.
Singlera, Megarobo & Zencore Named to the Unicorns List of Forbes China 2022
2023-02-03
On January 30, Forbes China revealed its list of emerging unicorns in China for 2022. Forbes China tracked more than 2,000 startups that raised more than RMB 200 million or USD 30 million in a single round of funding in the past year and are likely to cross over into the unicorn category.
Merck Announces Fourth-Quarter and Full-Year 2022 Financial Results
2023-02-03
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the fourth quarter and full year of 2022.
Roche Planning 2024 Launch of Automated Mass Spec Clinical Analyzer
2023-02-03
Roche Diagnostics plans to bring a fully automated mass spectrometry-based clinical analyzer to market in 2024.
China Travel Restrictions & COVID-19 Situation (Updated February 2, 2023)
2023-02-02
After three years, China announced its reopening from January 8, 2023. Passengers can enter China without quarantine. All you need is a negative PCR result within 48 hours before departure. You do not need to apply for a health code.
Beckman Coulter Partners with MeMed to Develop, Commercialize Host Immune Response Test
2023-02-02
Beckman Coulter Diagnostics announced on Tuesday that it has entered a strategic partnership with Israeli diagnostic company MeMed to develop and commercialize a host immune response diagnostic test.
Thermo Fisher Scientific Reports Fourth Quarter and Full Year 2022 Results
2023-02-02
Thermo Fisher Scientific Inc., the world leader in serving science, today reported its financial results for the fourth quarter and full year ended December 31, 2022.
DAAN GENE: expected 2022 full-year earnings of 5.1 to 5.8 billion with net profit up 40.95% to 60.3% year-on-year
2023-02-01
On January 31, A-share listed Daan Gene released the 2022 full-year performance forecast.
Guardant360 CDx breast cancer liquid biopsy test receives FDA approval as companion diagnostic
2023-02-01
Precision oncology company Guardant Health announced on Monday that FDA has approved its Guardant360 CDx liquid biopsy test as a companion diagnostic.
SQI Diagnostics Reports Fourth Quarter and Fiscal 2022 Results
2023-02-01
SQI Diagnostics Inc., a leader in the science of lung health that develops and manufactures respiratory health and precision medicine tests today reported its financial and operational results for the fourth quarter and fiscal year ended September 30, 2022.
Wuhan Easy Diagnosis Biomedicine's net profit may reach 5 billion by 2022
2023-01-31
Easy Diagnosis released a performance preview on the evening of January 30, expecting 2022 net profit attributable to shareholders of listed companies of CNY4.6 billion to CNY5 billion, an increase of 225.5% to 253.8%; basic earnings per share of about CNY29.99 to CNY32.60.
GE HealthCare Reports Fourth Quarter and Full Year 2022 Financial Results
2023-01-31
GE HealthCare (Nasdaq: GEHC), a leading global precision care innovator, reported financial results for the fourth quarter and full year ended December 31, 2022.
Danaher Reports Fourth Quarter and Full Year 2022 Results
2023-01-31
Danaher Corporation (NYSE: DHR) (the "Company") announced results for the fourth quarter and full year 2022. All results in this release reflect only continuing operations unless otherwise noted. Net earnings refers to net earnings attributable to common shareholders.
Andon Health earns 17.5 billion CNY a year by selling antigen reagents!
2023-01-30
On the evening of January 19, Andon Health Co., Ltd. released the 2022 performance forecast, and it is expected that the company's net profit in 2022 will be 16.5 billion CNY to 17.5 billion CNY, a year-on-year increase of 1715.9% to 1825.95%.
Total:
3024
Pages:
202
First
Prev
1
..
69
70
71
72
73
74
75
..
202
Next
End